Orthocell (ASX:OCC) appointed medical device distribution company LEDA Orthopaedics as the exclusive in-country distributor of its nerve repair product Remplir in the UK, according to a Tuesday Australian bourse filing.
Orthocell's regulatory submission process to the British Standards Institution in December 2025 sought approval to commercially distribute Remplir in the UK and Europe, and regulatory approval is expected in the third quarter.
Its shares jumped 3% in recent trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.